Belimumab: A BLyS-Specific Inhibitor for the Treatment of Systemic Lupus Erythematosus

Current and novel therapeutics in the treatment of systemic lupus erythematosus

(2011) Cagri Yildirim-Toruner et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

(2009) Daniel J. Wallace et al.   ARTHRITIS AND RHEUMATISM

Novel evidence-based systemic lupus erythematosus responder index

(2009) Richard A. Furie et al.   ARTHRITIS AND RHEUMATISM

Systemic lupus erythematosus clinical trials—an interim analysis

(2009) Maria Dall'Era et al.   Nature Reviews Rheumatology

Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects

(2009) Fanny Monneaux et al.   ARTHRITIS RESEARCH & THERAPY

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

(2008) Richard Furie et al.   ARTHRITIS RESEARCH & THERAPY